BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease and long COVID) and advanced liver disease.
In neurodegenerative disease, the company’s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival).
News
BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial
Executive Interviews
BioVie completes enrollment in Long COVID trial as need for treatments grows
